Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains

Orientation: Pharmaceutical supply chains (SCs) are experiencing a growing emergence of illicit trade of counterfeited products. This threat is amplified because of global distributed SC networks, increased access to the Internet and challenging economic conditions. Research purpose: The purpose of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christine Terblanche, Wesley Niemann
Formato:	article
Lenguaje:	EN
Publicado:	AOSIS 2021
Materias:	supply chain risk mitigation supply chain resilience counterfeiting pharmaceutical firms qualitative south africa Management. Industrial management HD28-70 Business HF5001-6182
Acceso en línea:	https://doaj.org/article/8f419b873a5f4618b25caafe4d8ceecf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f419b873a5f4618b25caafe4d8ceecf
record_format	dspace
spelling	oai:doaj.org-article:8f419b873a5f4618b25caafe4d8ceecf2021-11-24T07:29:06ZCounterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains2413-19031684-199910.4102/ac.v21i1.963https://doaj.org/article/8f419b873a5f4618b25caafe4d8ceecf2021-11-01T00:00:00Zhttps://actacommercii.co.za/index.php/acta/article/view/963https://doaj.org/toc/2413-1903https://doaj.org/toc/1684-1999Orientation: Pharmaceutical supply chains (SCs) are experiencing a growing emergence of illicit trade of counterfeited products. This threat is amplified because of global distributed SC networks, increased access to the Internet and challenging economic conditions. Research purpose: The purpose of this study was to explore risk mitigation capabilities and SC resilience (SCRES) to reduce the effects of counterfeiting in the South African pharmaceutical industry. Motivation for the study: Developing countries such as South Africa tend to be more vulnerable to counterfeiting, as these countries do not have established responses that are seen in more developed countries, such as SC regulation, track-and-trace technology and enforcement regimes. Research design, approach and method: This study employed a generic qualitative research design. Semi-structured interviews were used to collect data from 12 pharmaceutical manufacturers, distributors and retailers in the South African pharmaceutical industry. A thematic analysis approach was followed to analyse the collected data. Main findings: The findings show that the sources of counterfeiting stem from the local and outsourced manufacturing of counterfeited products, presence of unauthorised distributors and importing of counterfeit products. Risk awareness can be enhanced by collaborating with industry members, training members to identify counterfeits and by developing authentication technologies. The industry actively combats counterfeiting by using SCRES enablers including visibility, collaboration, information sharing and by developing an SC risk management culture. Practical/managerial implications: South African pharmaceutical firms have limited resilience. Therefore, managers should develop flexibility, agility, sensing and redundancy as resilience enables firms to combat counterfeiting. Contribution/value-add: This study expands the current literature by identifying the unique sources of counterfeiting and risk mitigation capabilities to combat counterfeiting in pharmaceutical firms in a developing country context.Christine TerblancheWesley NiemannAOSISarticlesupply chain risk mitigationsupply chain resiliencecounterfeitingpharmaceutical firmsqualitativesouth africaManagement. Industrial managementHD28-70BusinessHF5001-6182ENActa Commercii, Vol 21, Iss 1, Pp e1-e13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	supply chain risk mitigation supply chain resilience counterfeiting pharmaceutical firms qualitative south africa Management. Industrial management HD28-70 Business HF5001-6182
spellingShingle	supply chain risk mitigation supply chain resilience counterfeiting pharmaceutical firms qualitative south africa Management. Industrial management HD28-70 Business HF5001-6182 Christine Terblanche Wesley Niemann Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
description	Orientation: Pharmaceutical supply chains (SCs) are experiencing a growing emergence of illicit trade of counterfeited products. This threat is amplified because of global distributed SC networks, increased access to the Internet and challenging economic conditions. Research purpose: The purpose of this study was to explore risk mitigation capabilities and SC resilience (SCRES) to reduce the effects of counterfeiting in the South African pharmaceutical industry. Motivation for the study: Developing countries such as South Africa tend to be more vulnerable to counterfeiting, as these countries do not have established responses that are seen in more developed countries, such as SC regulation, track-and-trace technology and enforcement regimes. Research design, approach and method: This study employed a generic qualitative research design. Semi-structured interviews were used to collect data from 12 pharmaceutical manufacturers, distributors and retailers in the South African pharmaceutical industry. A thematic analysis approach was followed to analyse the collected data. Main findings: The findings show that the sources of counterfeiting stem from the local and outsourced manufacturing of counterfeited products, presence of unauthorised distributors and importing of counterfeit products. Risk awareness can be enhanced by collaborating with industry members, training members to identify counterfeits and by developing authentication technologies. The industry actively combats counterfeiting by using SCRES enablers including visibility, collaboration, information sharing and by developing an SC risk management culture. Practical/managerial implications: South African pharmaceutical firms have limited resilience. Therefore, managers should develop flexibility, agility, sensing and redundancy as resilience enables firms to combat counterfeiting. Contribution/value-add: This study expands the current literature by identifying the unique sources of counterfeiting and risk mitigation capabilities to combat counterfeiting in pharmaceutical firms in a developing country context.
format	article
author	Christine Terblanche Wesley Niemann
author_facet	Christine Terblanche Wesley Niemann
author_sort	Christine Terblanche
title	Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
title_short	Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
title_full	Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
title_fullStr	Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
title_full_unstemmed	Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains
title_sort	counterfeiting: exploring mitigation capabilities and resilience in south african pharmaceutical supply chains
publisher	AOSIS
publishDate	2021
url	https://doaj.org/article/8f419b873a5f4618b25caafe4d8ceecf
work_keys_str_mv	AT christineterblanche counterfeitingexploringmitigationcapabilitiesandresilienceinsouthafricanpharmaceuticalsupplychains AT wesleyniemann counterfeitingexploringmitigationcapabilitiesandresilienceinsouthafricanpharmaceuticalsupplychains
_version_	1718415925141569536

Counterfeiting: Exploring mitigation capabilities and resilience in South African pharmaceutical supply chains

Ejemplares similares